Peripheral arterial disease in diabetes - A review

Diabetic Medicine

Volumn 27, Issue 1, 2010, Pages 4-14

  Jude, E B ^a   Eleftheriadou, I ^b   Tentolouris, N ^b  

^a TAMESIDE GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Ankle brachial pressure index; Diabetes; Peripheral arterial disease; Risk factors; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CILOSTAZOL; CLOPIDOGREL; DIPYRIDAMOLE; ILOPROST; PENTOXIFYLLINE; PLACEBO; SULFINPYRAZONE; TICLOPIDINE;

ANGIOGENESIS; ANKLE BRACHIAL INDEX; ARTERY DISEASE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CLINICAL FEATURE; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC PATIENT; DIAGNOSTIC TEST; DISEASE COURSE; DRUG OVERDOSE; DYSLIPIDEMIA; GLYCEMIC CONTROL; HEART INFARCTION; HUMAN; HYPERFIBRINOGENEMIA; HYPERGLYCEMIA; HYPERHOMOCYSTEINEMIA; HYPERTENSION; INCIDENCE; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INTERMITTENT CLAUDICATION; LEG ISCHEMIA; LIFESTYLE MODIFICATION; LIMB AMPUTATION; MONOTHERAPY; MORBIDITY; MORTALITY; NEUTROPENIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PREVALENCE; REVASCULARIZATION; REVIEW; RISK FACTOR; STROKE; THROMBOTIC THROMBOCYTOPENIC PURPURA; UNSPECIFIED SIDE EFFECT;

AMPUTATION; ANKLE BRACHIAL INDEX; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; MALE; PERIPHERAL ARTERIAL DISEASE; RISK FACTORS; RISK REDUCTION BEHAVIOR;

EID: 73949152177     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2009.02866.x     Document Type: Review

References (60)

1. American Diabetes Association. Peripheral arterial disease in people with diabetes. Diabetes Care 2003 26 : 3333 3341.
2. Jude EB. Intermittent claudication in the patient with diabetes. Br J Diabetes Vasc Dis 2004 4 : 238 242.
3. Jude EB, Oyibo SO, Chalmers N, Boulton AJ. Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome. Diabetes Care 2001 24 : 1433 1437.
4. Kannel WB, McGee DL. Update on some epidemiologic features of intermittent claudication: the Framingham Study. J Am Geriatr Soc 1985 33 : 13 18.
5. Melton LJ III., Macken KM, Palumbo PJ, Elveback LR. Incidence and prevalence of clinical peripheral vascular disease in a population-based cohort of diabetic patients. Diabetes Care 1980 3 : 650 654.
6. Beks PJ, Mackaay AJ, de Neeling JN, de Vries H, Bouter LM, Heine RJ. Peripheral arterial disease in relation to glycaemic level in an elderly Caucasian population: the Hoorn study. Diabetologia 1995 38 : 86 96.
7. Elhadd T, Robb R, Jung R, Stonebridge P, Belch J. Pilot study of prevalence of asymptomatic peripheral arterial occlusive disease in patients with diabetes attending a hospital clinic. Pract Diabetes Int 1999 16 : 163 166.
8. Welborn TA, Knuiman M, McCann V, Stanton K, Constable IJ. Clinical macrovascular disease in Caucasoid diabetic subjects: logistic regression analysis of risk variables. Diabetologia 1984 27 : 568 573.
9. Walters DP, Gatling W, Mullee MA, Hill RD. The prevalence, detection, and epidemiological correlates of peripheral vascular disease: a comparison of diabetic and non-diabetic subjects in an English community. Diabet Med 1992 9 : 710 715.
10. Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg 2000 31 : S1 S296.
11. Olson JC, Erbey JR, Forrest KY, Williams K, Becker DJ, Orchard TJ. Glycemia (or, in women, estimated glucose disposal rate) predict lower extremity arterial disease events in type 1 diabetes. Metabolism 2002 51 : 248 254.
12. Faglia E, Favales F, Quarantiello A, Calia P, Clelia P, Brambilla G et al. Angiographic evaluation of peripheral arterial occlusive disease and its role as a prognostic determinant for major amputation in diabetic subjects with foot ulcers. Diabetes Care 1998 21 : 625 630.
13. Malmstedt J, Leander K, Wahlberg E, Karlstrom L, Alfredsson L, Swedenborg J. Outcome after leg bypass surgery for critical limb ischemia is poor in patients with diabetes: a population-based cohort study. Diabetes Care 2008 31 : 887 892.
14. Faglia E, Clerici G, Clerissi J, Gabrielli L, Losa S, Mantero M et al. Early and five-year amputation and survival rate of diabetic patients with critical limb ischemia: data of a cohort study of 564 patients. Eur J Vasc Endovasc Surg 2006 32 : 484 490.
15. Murabito JM, Evans JC, Nieto K, Larson MG, Levy D, Wilson PW. Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study. Am Heart J 2002 143 : 961 965.
16. Abbott RD, Brand FN, Kannel WB. Epidemiology of some peripheral arterial findings in diabetic men and women: experiences from the Framingham Study. Am J Med 1990 88 : 376 381.
17. Adler AI, Stevens RJ, Neil A, Stratton IM, Boulton AJ, Holman RR. UKPDS 59: hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes. Diabetes Care 2002 25 : 894 899.
18. Zander E, Heinke P, Reindel J, Kohnert KD, Kairies U, Braun J et al. Peripheral arterial disease in diabetes mellitus type 1 and type 2: are there different risk factors? Vasa 2002 31 : 249 254.
19. Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 2008 359 : 1565 1576.
20. Laakso M, Pyorala K. Lipid and lipoprotein abnormalities in diabetic patients with peripheral vascular disease. Atherosclerosis 1988 74 : 55 63.
21. Katsilambros NL, Tsapogas PC, Arvanitis MP, Tritos NA, Alexiou ZP, Rigas KL. Risk factors for lower extremity arterial disease in non-insulin-dependent diabetic persons. Diabet Med 1996 13 : 243 246.
22. James RW, Boemi M, Sirolla C, Amadio L, Fumelli P, Pometta D. Lipoprotein (a) and vascular disease in diabetic patients. Diabetologia 1995 38 : 711 714.
23. O'Neal DN, Lewicki J, Ansari MZ, Matthews PG, Best JD. Lipid levels and peripheral vascular disease in diabetic and non-diabetic subjects. Atherosclerosis 1998 136 : 1 8.
24. Bonora E, Formentini G, Calcaterra F, Lombardi S, Marini F, Zenari L et al. HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. Diabetes Care 2002 25 : 1135 1141.
25. Cheng SW, Ting AC, Wong J. Fasting total plasma homocysteine and atherosclerotic peripheral vascular disease. Ann Vasc Surg 1997 11 : 217 223.
26. Gosk-Bierska I, Adamiec R, Alexewicz P, Wysokinski WE. Coagulation in diabetic and non-diabetic claudicants. Int Angiol 2002 21 : 128 133.
27. Jude EB, Douglas JT, Anderson SG, Young MJ, Boulton AJ. Circulating cellular adhesion molecules ICAM-1, VCAM-1, P- and E-selectin in the prediction of cardiovascular disease in diabetes mellitus. Eur J Intern Med 2002 13 : 185 189.
28. Marso SP, Hiatt WR. Peripheral arterial disease in patients with diabetes. J Am Coll Cardiol 2006 47 : 921 929.
29. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002 287 : 2570 2581.
30. Uemura S, Matsushita H, Li W, Glassford AJ, Asagami T, Lee KH et al. Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress. Circ Res 2001 88 : 1291 1298.
31. Li Y, Woo V, Bose R. Platelet hyperactivity and abnormal Ca(2+) homeostasis in diabetes mellitus. Am J Physiol Heart Circ Physiol 2001 280 : H1480 H1489.
32. Vinik AI, Erbas T, Park TS, Nolan R, Pittenger GL. Platelet dysfunction in type 2 diabetes. Diabetes Care 2001 24 : 1476 1485.
33. Carr ME. Diabetes mellitus: a hypercoagulable state. J Diabetes Complications 2001 15 : 44 54.
34. Hirsch AT, Hiatt WR. PAD awareness, risk, and treatment: new resources for survival - the USA PARTNERS program. Vasc Med 2001 6 : 9 12.
35. Dyet JF, Nicholson AA, Ettles DF. Vascular imaging and intervention in peripheral arteries in the diabetic patient. Diabetes Metab Res Rev 2000 16 (Suppl. 1 S16 S22.
36. Moulik PK, Mtonga R, Gill GV. Amputation and mortality in new-onset diabetic foot ulcers stratified by etiology. Diabetes Care 2003 26 : 491 494.
37. Dolan NC, Liu K, Criqui MH, Greenland P, Guralnik JM, Chan C et al. Peripheral artery disease, diabetes, and reduced lower extremity functioning. Diabetes Care 2002 25 : 113 120.
38. Carser DG. Do we need to reappraise our method of interpreting the ankle brachial pressure index? J Wound Care 2001 10 : 59 62.
39. Costacou T, Huskey ND, Edmundowicz D, Stolk R, Orchard TJ. Lower-extremity arterial calcification as a correlate of coronary artery calcification. Metabolism 2006 55 : 1689 1696.
40. Aboyans V, Ho E, Denenberg JO, Ho LA, Natarajan L, Criqui MH. The association between elevated ankle systolic pressures and peripheral occlusive arterial disease in diabetic and nondiabetic subjects. J Vasc Surg 2008 48 : 1197 1203.
41. Tsai JC, Chan P, Wang CH, Jeng C, Hsieh MH, Kao PF et al. The effects of exercise training on walking function and perception of health status in elderly patients with peripheral arterial occlusive disease. J Intern Med 2002 252 : 448 455.
42. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008 359 : 1577 1589.
43. Dormandy JA, Betteridge DJ, Schernthaner G, Pirags V, Norgren L. Impact of peripheral arterial disease in patients with diabetes - results from PROactive (PROactive 11). Atherosclerosis 2009 202 : 272 281.
44. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997 20 : 614 620.
45. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002 360 : 7 22.
46. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004 364 : 685 696.
47. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000 355 : 253 259.
48. Mehler PS, Coll JR, Estacio R, Esler A, Schrier RW, Hiatt WR. Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes. Circulation 2003 107 : 753 756.
49. Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Arch Intern Med 1991 151 : 1769 1776.
50. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994 308 : 81 106.
51. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - II: maintenance of vascular graft or arterial patency by antiplatelet therapy. Antiplatelet Trialists' Collaboration. BMJ 1994 308 : 159 168.
52. Hess H, Mietaschk A, Deichsel G. Drug-induced inhibition of platelet function delays progression of peripheral occlusive arterial disease. A prospective double-blind arteriographically controlled trial. Lancet 1985 1 : 415 419.
53. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996 348 : 1329 1339.
54. Chapman TM, Goa KL. Cilostazol: a review of its use in intermittent claudication. Am J Cardiovasc Drugs 2003 3 : 117 138.
55. Rendell M, Cariski AT, Hittel N, Zhang P. Cilostazol treatment of claudication in diabetic patients. Curr Med Res Opin 2002 18 : 479 487.
56. Cozzolino D, Coppola L, Masi S, Salvatore T, Sasso FC, De Lucia D et al. Short- and long-term treatments with iloprost in diabetic patients with peripheral vascular disease: effects on the cardiovascular risk factor plasminogen activator inhibitor type-1. Eur J Clin Pharmacol 1999 55 : 491 497.
57. Papanas N, Maltezos E. Advances in treating the ischaemic diabetic foot. Curr Vasc Pharmacol 2008 6 : 23 28.
58. Yang XF, Wu YX, Wang HM, Xu YF, Lu X, Zhang YB et al. Autologous peripheral blood stem cells transplantation in treatment of 62 cases of lower extremity ischemic disorder Zhonghua Nei Ke Za Zhi 2005 44 : 95 98.
59. Maca TH, Ahmadi R, Derfler K, Ehringer H, Gschwandtner ME, Horl W et al. Influence of lipoprotein(a) on restenosis after femoropopliteal percutaneous transluminal angioplasty in Type 2 diabetic patients. Diabet Med 2002 19 : 300 306.
60. Panneton JM, Gloviczki P, Bower TC, Rhodes JM, Canton LG, Toomey BJ. Pedal bypass for limb salvage: impact of diabetes on long-term outcome. Ann Vasc Surg 2000 14 : 640 647.